Market Size of Antibiotics Industry
Study Period | 2021 - 2029 |
Market Size (2024) | USD 53.43 Billion |
Market Size (2029) | USD 65.22 Billion |
CAGR (2024 - 2029) | 4.07 % |
Fastest Growing Market | Asia Pacific |
Largest Market | North America |
Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
Antibiotics Market Analysis
The Antibiotics Market size is estimated at USD 53.43 billion in 2024, and is expected to reach USD 65.22 billion by 2029, growing at a CAGR of 4.07% during the forecast period (2024-2029).
The outbreak of COVID-19 impacted the antibiotics market. During the initial phase of the pandemic, the demand for antibiotics significantly increased for treating COVID-19. For instance, in March 2020, Pfizer announced positive data by using azithromycin (Zithromax) and hydroxychloroquine in a coronavirus (COVID-19) clinical trial, performed in France. Following these clinical trials, azithromycin became a widely used drug for treating COVID-19. Furthermore, according to a July 2021 NCBI research article and as per the Mordor Intelligence analysis, COVID-19 contributed to about 216.0 million excess doses of non-CAF (child-appropriate formulations) of antibiotics in total and 38 million extra doses of azithromycin between June and September 2020 in India. Therefore, the market witnessed high growth during the pandemic due to such high demand for antibiotics. However, it is expected to observe stable growth after the pandemic.
The emergence of Anti-MRSA/VRE drugs, the increasing burden of infectious diseases, the vulnerable aging population, and the need for effective and newer antibiotics are driving the market growth. For instance, according to the October 2022 report of the WHO, around 10.6 million people suffered from TB in 2021. It was an increase of 4.5% from 2020, and 1.6 million people died from TB across the globe. The same source also reported that the burden of drug-resistant TB (DR-TB) increased by 3.0% between 2020 and 2021, with 450000 new cases of rifampicin-resistant TB (RR-TB) in 2021. Furthermore, one-third of the cases were reported from eight countries, including India, China, Indonesia, Philippines, Pakistan, Nigeria, Bangladesh, and South Africa. Therefore, such a high prevalence of infectious diseases may propel the demand for antibiotics, further surging market growth.
The urbanization and destruction of natural habitats, climate change, and changing ecosystems are three major factors contributing to the high rate of infectious diseases in all age groups. For instance, as per the UNICEF data published in August 2022, there were more than 1,400 cases of pneumonia per 100,000 children, or 1 case in 71 children each year, globally, with the highest incidence occurring in South Asia (2,500 cases per 100,000 children) and West and Central Africa (1,620 cases per 100,000 children). Similarly, as per the ERS journal of 2021, it was estimated that around 36,580,965 Europeans suffered from COPD in 2020. According to Mordor Intelligence analysis, approximately 49,453,852 Europeans will suffer from COPD in 2050. Antibiotics are widely used for treating various types of diseases. Therefore, such a high disease prevalence is anticipated to impact the market growth over the forecast period positively.
However, factors such as antibiotic resistance and fewer companies involved in active research are expected to impede the growth of the antibiotics market over the forecast period.
Antibiotics Industry Segmentation
As per the scope of the report, antibiotic medicines refer to medicines used to treat infections by killing bacteria. These are among the most prescribed courses worldwide in fighting bacterial infections, primarily in outpatient settings. The Antibiotics Market is segmented by product (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenems, Aminoglycosides, Sulfonamides, and other product types), spectrum (broad-spectrum antibiotics, narrow-spectrum antibiotics, and other spectrums), and geography (North America, Europe, Asia-Pacific, Middle East, and Africa, and South America). The report also covers the estimated market sizes and trends for 17 countries across major global regions. The report offers values (in USD million) for the above segments.
By Product Type | |
Cephalosporins | |
Penicillins | |
Fluroquinilones | |
Macrolides | |
Carbapenems | |
Aminoglycosides | |
Sulfonamides | |
Other Product Types |
By Spectrum | |
Broad-spectrum Antibiotics | |
Narrow-spectrum Antibiotics |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Antibiotics Market Size Summary
The antibiotics market is poised for steady growth over the forecast period, driven by several key factors. The demand for antibiotics surged during the COVID-19 pandemic, particularly with the use of azithromycin for treating the virus, which significantly boosted market growth. However, post-pandemic, the market is expected to stabilize. The increasing prevalence of infectious diseases, the emergence of Anti-MRSA/VRE drugs, and the need for newer antibiotics are contributing to the market's expansion. Urbanization, climate change, and changing ecosystems are also leading to a higher incidence of infectious diseases, further propelling the demand for antibiotics. Despite these growth drivers, challenges such as antibiotic resistance and limited research activity by pharmaceutical companies may hinder market progress.
The cephalosporin segment, in particular, is expected to experience considerable growth due to its broad applicability and effectiveness against various infections. The segment's expansion is supported by strategic acquisitions and product launches, such as Sandoz's acquisition of GSK's cephalosporin business. North America is anticipated to dominate the antibiotics market, driven by high demand and consumption due to the burden of infectious diseases and an aging population. The competitive landscape is characterized by a few major players, including Johnson & Johnson, Pfizer, and Bayer, who hold significant market shares. These companies are actively involved in expanding their product offerings and forming strategic partnerships to strengthen their market positions.
Antibiotics Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Emergence of Anti-MRSA/VRE Drugs
-
1.2.2 Increasing Burden of Infectious Diseases
-
1.2.3 Vulnerable Aging Population
-
-
1.3 Market Restraints
-
1.3.1 Antibiotic Resistance
-
1.3.2 Fewer Companies Involved in Active Research
-
-
1.4 Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD Million)
-
2.1 By Product Type
-
2.1.1 Cephalosporins
-
2.1.2 Penicillins
-
2.1.3 Fluroquinilones
-
2.1.4 Macrolides
-
2.1.5 Carbapenems
-
2.1.6 Aminoglycosides
-
2.1.7 Sulfonamides
-
2.1.8 Other Product Types
-
-
2.2 By Spectrum
-
2.2.1 Broad-spectrum Antibiotics
-
2.2.2 Narrow-spectrum Antibiotics
-
-
2.3 Geography
-
2.3.1 North America
-
2.3.1.1 United States
-
2.3.1.2 Canada
-
2.3.1.3 Mexico
-
-
2.3.2 Europe
-
2.3.2.1 Germany
-
2.3.2.2 United Kingdom
-
2.3.2.3 France
-
2.3.2.4 Italy
-
2.3.2.5 Spain
-
2.3.2.6 Rest of Europe
-
-
2.3.3 Asia-Pacific
-
2.3.3.1 China
-
2.3.3.2 Japan
-
2.3.3.3 India
-
2.3.3.4 Australia
-
2.3.3.5 South Korea
-
2.3.3.6 Rest of Asia-Pacific
-
-
2.3.4 Middle East and Africa
-
2.3.4.1 GCC
-
2.3.4.2 South Africa
-
2.3.4.3 Rest of Middle-East and Africa
-
-
2.3.5 South America
-
2.3.5.1 Brazil
-
2.3.5.2 Argentina
-
2.3.5.3 Rest of South America
-
-
-
Antibiotics Market Size FAQs
How big is the Antibiotics Market?
The Antibiotics Market size is expected to reach USD 53.43 billion in 2024 and grow at a CAGR of 4.07% to reach USD 65.22 billion by 2029.
What is the current Antibiotics Market size?
In 2024, the Antibiotics Market size is expected to reach USD 53.43 billion.